Ionis Pharmaceuticals Inc at William Blair Growth Stock Conference Transcript
Thanks, everyone, for joining us here today at the William Blair Growth Stock Conference. My name is Myles Minter. I'm a biotech analyst here at William Blair, who covers Ionis Pharmaceuticals, which is the topic of today.
Just have to point you to a complete list of research disclosures and potential conflicts of interest that are all listed at williamblair.com. And with those formalities out of the way, my pleasure to introduce Beth Hougen, who is the Chief Financial Officer at Ionis Pharmaceuticals; and also Eric Swayze, the Senior Vice President of Research there. So thanks for joining us today.
Just to kick off this fireside chat. Ionis has been around since 1989. It's a long time, and you've really built up to be in that leadership position for antisense oligonucleotides. I think most of our listeners are probably familiar with the company from the SPINRAZA success in collaboration with Biogen. It's really been a game-changing therapy for those SMA patients, but there's 40 other -- well, more than
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |